Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Gain Therapeutics (GANX).
Gain Therapeutics, Inc. has successfully completed the multiple ascending dose phase of its pioneering Phase 1 study for GT-02287, a promising new treatment for Parkinson’s Disease, with no serious adverse events or discontinuations reported. This milestone, announced on July 9, 2024, represents a key advancement in the development of novel therapies for neurological conditions, potentially signaling hope for patients and investors alike.
See more insights into GANX stock on TipRanks’ Stock Analysis page.